Outset Medical, Inc.OM

Outset Medical, Inc. (OM) reported a net loss of $19.0 million in Q1 2026 despite $27.9 million in revenue, according to its latest 10-Q filing. The San Francisco-based dialysis technology firm burned $12.8 million in operating cash, raising questions about its path to profitability amid rising inventory levels ($49.6 million) and R&D spending ($5.6 million).

Outset’s core business revolves around its OM System, a portable dialysis machine designed for home and clinical use. However, the company’s financials tell a story of scaling struggles: cash reserves stood at $30.6 million, while short-term investments totaled $126.1 million, suggesting liquidity isn’t the immediate concern-execution is. The recent departure of Executive Vice President Marc Nash, who oversaw R&D and operations, adds uncertainty to its product pipeline.

Shareholders approved the 2025 executive compensation package in June 2026 on a non-binding basis, a vote that passed despite the company’s ongoing losses. This follows a trend of boards betting on long-term growth even as near-term financial metrics deteriorate. With inventory up 4.5% quarter-over-quarter and no major regulatory approvals announced, investors are left wondering if the company’s bets will pay off.

Technically, OM shares have traded between $8.20 and $14.40 over the past year, though the stock’s volume remains thin (average daily volume: ~250,000 shares). The lack of catalysts and persistent cash burn could keep the equity range-bound unless the company secures new partnerships or clears a regulatory hurdle for its OM System expansion.